Erythropoietin therapy for acute stroke is both safe and beneficial.
BACKGROUND
Erythropoietin (EPO) and its receptor play a major role in embryonic brain, are weakly expressed in normal postnatal/adult brain and up-regulated upon metabolic stress. EPO protects neurons from hypoxic/ ischemic injury. The objective of this trial is to study the safety and efficacy of recombinant human EPO (rhEPO) for treatment of ischemic stroke in man.


METHODS
The trial consisted of a safety part and an efficacy part. In the safety study, 13 patients received rhEPO intravenously (3.3 X 10(4) IU/50 ml/30 min) once daily for the first 3 days after stroke. In the double-blind randomized proof-of-concept trial, 40 patients received either rhEPO or saline. Inclusion criteria were age <80 years, ischemic stroke within the middle cerebral artery territory confirmed by diffusion-weighted MRI, symptom onset <8 hr before drug administration, and deficits on stroke scales. The study endpoints were functional outcome at day 30 (Barthel Index, modified Rankin scale), NIH and Scandinavian stroke scales, evolution of infarct size (sequential MRI evaluation using diffusion-weighted [DWI] and fluid-attenuated inversion recovery sequences [FLAIR]) and the damage marker S100ss.


RESULTS
No safety concerns were identified. Cerebrospinal fluid EPO increased to 60-100 times that of nontreated patients, proving that intravenously administered rhEPO reaches the brain. In the efficacy trial, patients received rhEPO within 5 hr of onset of symptoms (median, range 2:40-7:55). Admission neurologic scores and serum S100beta concentrations were strong predictors ofoutcome. Analysis of covariance controlled for these two variables indicated that rhEPO treatment was associated with an improvement in follow-up and outcome scales. A strong trend for reduction in infarct size in rhEPO patients as compared to controls was observed by MRI.


CONCLUSIONS
Intravenous high-dose rhEPO is well tolerated in acute ischemic stroke and associated with an improvement in clinical outcome at 1 month. A larger scale clinical trial is warranted.
Ehrenreich
Hannelore
H
Max-Planck-Institute for Experimental Medicine, Departments of Neurology and Psychiatry, Georg-August-University, Goettingen, Germany. ehrenreich@em.mpg.de
Hasselblatt
Martin
M
Dembowski
Christoph
C
Cepek
Lukas
L
Lewczuk
Piotr
P
Stiefel
Michael
M
Rustenbeck
Hans-Heino
HH
Breiter
Norbert
N
Jacob
Sonja
S
Knerlich
Friederike
F
Bohn
Matthias
M
Poser
Wolfgang
W
Rüther
Eckart
E
Kochen
Michael
M
Gefeller
Olaf
O
Gleiter
Christoph
C
Wessel
Thomas C
TC
De Ryck
Marc
M
Itri
Loretta
L
Prange
Hilmar
H
Cerami
Anthony
A
Brines
Michael
M
Sirén
Anna-Leena
AL
D001792:Blood Platelets / Q000187:drug effects; D004311:Double-Blind Method; D004912:Erythrocytes / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage*; D006400:Hematocrit; D006801:Humans; D007262:Infusions, Intravenous; D020521:Stroke / Q000188:drug therapy*; D013997:Time Factors
D004921:Erythropoietin